Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Impedimed Limited ( (AU:IPD) ) has issued an announcement.
Impedimed Limited has applied to the ASX for quotation of 448,097 ordinary fully paid shares issued to its non-executive directors under the company’s Non-Executive Director Share Plan, representing 15% of director fees for the quarter ended 31 December 2025. The move reflects the company’s ongoing practice of aligning board remuneration with shareholder interests by partially paying director fees in equity, modestly increasing the company’s quoted share capital and reinforcing governance incentives for its non-executive directors.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited, listed on the ASX under the code IPD, operates in the medical technology sector, specialising in diagnostic and monitoring solutions, with its shares traded as ordinary fully paid securities on the Australian market.
Average Trading Volume: 1,179,706
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$71.34M
For detailed information about IPD stock, go to TipRanks’ Stock Analysis page.